




PHARMACEUTICAL 2020

Unity Biotechnology Inc.
Rank 120 of 358





RealRate

PHARMACEUTICAL 2020

Unity Biotechnology Inc. Rank 120 of 358



The relative strengths and weaknesses of Unity Biotechnology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Unity Biotechnology Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 102% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	129,487
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,216
Liabilities, Non-Current	0
Other Assets	5,098
Other Compr. Net Income	185
Other Expenses	-1,352
Other Liabilities	13,298
Other Net Income	7,474
Other Revenues	0
Property and Equipment	16,636
Research and Development	70,957
Selling, General and Administrative Expense	20,046

Output Variable	Value in 1000 USD
Assets	151,221
Liabilities	30,514
Expenses	89,651
Revenues	0
Stockholders Equity	120,707
Net Income	-82,177
Comprehensive Net Income	-82,084
Economic Capital Ratio	138%